IP Library Granted Patent US 8,809,619
Granted Patent B2
US 8,809,619 · App. 12/679,570 · Granted Aug 19, 2014

Knockout mice for a P450 gene cluster

Inventors: Nico Scheer (Cologne, DE); Charles Roland Wolf (Dundee, GB)
Assignee: ITI Scotland Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,809,619
App. No.
12/679,570
Granted
Aug 19, 2014
Kind
B2
Abstract

The invention relates to the generation of mouse models of drug metabolism in which clusters of genes that are involved in drug metabolism have been knocked out. The development of new drugs and chemicals for therapeutic use or for other purposes is extremely complex. Of particular importance is the understanding of how these chemical agents are handled in the body, whether they have appropriate pharmacokinetics and whether, as a consequence of metabolism, any safety issues arise. Many of the proteins that are involved in the metabolism, disposition and elimination of drugs are members of multigene families that exhibit very marked species differences in gene number, function and regulation. For these reasons, experiments carried out in laboratory animals to establish routes of metabolism or toxicity can be severely compromised and, as a consequence, do not faithfully represent the human situation. One example of this complexity is reflected in the mammalian cytochrome P450 system, where the sizes of multigene families of proteins which carry out particular metabolic functions vary enormously between species.

Claims (3)

1. A transgenic mouse whose genome comprises a homozygous disruption of a Cyp3a gene cluster, wherein the mouse does not have Cyp3a activity and does not contain a gene from the human gene cluster.

2. The mouse according to claim 1 , wherein the disruption is a deletion of the entire Cyp3a gene cluster.

3. The mouse according to claim 2 , wherein the deletion is made by homologous recombination.

Assignments (6)
SECURITY INTEREST Recorded Nov 1, 2022
From: TACONIC BIOSCIENCES, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061608/0403 →
ASSIGNATION AND LISCENSE TERMINATION Recorded Oct 21, 2022
From: ITI SCOTLAND LIMITED
To: TACONIC BIOSCIENCES, INC.
Reel/Frame 061740/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2011
From: WOLF, CHARLES ROLAND
To: CXR BIOSCIENCES LTD.
Reel/Frame 026078/0777 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2011
From: CXR BIOSCIENCES LTD.
To: ITI SCOTLAND LIMITED
Reel/Frame 026078/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2011
From: ARTEMIS PHARMACEUTICAL GMBH
To: ITI SCOTLAND LIMITED
Reel/Frame 026078/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2011
From: SCHEER, NICO
To: ARTEMIS PHARMACEUTICAL GMBH
Reel/Frame 026079/0788 →
Priority Claims (1)
GB 0720552.9 · Oct 19, 2007 · national
Continuity (1)
Related Publication 20100333222A1 · Dec 30, 2010